Abstract:PURPOSE: We introduce two validated single (SH) and dual hormone (DH) mathematical models that represent an in-silico virtual patient population (VPP) for type 1 diabetes (T1D). The VPP can be used to evaluate automated insulin and glucagon delivery algorithms, so-called artificial pancreas (AP) algorithms that are currently being used to help people with T1D better manage their glucose levels. We present validation results comparing these virtual patients with true clinical patients undergoing AP control and demonstrate that the virtual patients behave similarly to people with T1D.METHODS: A single hormone virtual patient population (SH-VPP) was created that is comprised of eight differential equations that describe insulin kinetics, insulin dynamics and carbohydrate absorption. The parameters in this model that represent insulin sensitivity were statistically sampled from a normal distribution to create a population of virtual patients with different levels of insulin sensitivity. A dual hormone virtual patient population (DH-VPP) extended this SH-VPP by incorporating additional equations to represent glucagon kinetics and glucagon dynamics. The DH-VPP is comprised of thirteen differential equations and a parameter representing glucagon sensitivity, which was statistically sampled from a normal distribution to create virtual patients with different levels of glucagon sensitivity. We evaluated the SH-VPP and DH-VPP on a clinical data set of 20 people with T1D who participated in a 3.5-day outpatient AP study. Twenty virtual patients were matched with the 20 clinical patients by total daily insulin requirements and body weight. The identical meals given during the AP study were given to the virtual patients and the identical AP control algorithm that was used to control the glucose of the virtual patients was used on the clinical patients. We compared percent time in target range (70-180 mg/dL), time in hypoglycemia (<70 mg/dL) and time in hyperglycemia (>180 mg/dL) for both the virtual patients and the actual patients.RESULTS: The subjects in the SH-VPP performed similarly vs. the actual patients (time in range: 78.1 ± 5.1% vs. 74.3 ± 8.1%, p = 0.11; time in hypoglycemia: 3.4 ± 1.3% vs. 2.8 ± 1.7%, p = 0.23). The subjects in the DH-VPP also performed similarly vs. the actual patients (time in range: 75.6 ± 5.5% vs. 71.9 ± 10.9%, p = 0.13; time in hypoglycemia: 0.9 ± 0.8% vs. 1.3 ± 1%, p = 0.19). While the VPPs tended to over-estimate the time in range relative to actual patients, the difference was not statistically significant.CONCLUSIONS: We have verified that a SH-VPP and a DH-VPP performed comparably with actual patients undergoing AP control using an identical control algorithm. The SH-VPP and DH-VPP may be used as a simulator for pre-evaluation of T1D control algorithms.

GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review

Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility

Analysis of Glucose Responsive Glucagon Therapeutics using Computational Models of the Glucoregulatory System

The clinical experience of GLP-1 receptor agonist drugs

Dynamical modeling the effect of glucagon-like peptide on glucose-insulin regulatory system based on mice experimental observation

Modeling Glucose, Insulin, C-Peptide, and Lactate Interplay in Adolescents During an Oral Glucose Tolerance Test

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline

Approaches to Modeling Blood Glucose Dynamics In Type 1 Diabetic Patients for Insulin Pump Automation

Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

A comprehensive review of models and nonlinear control strategies for blood glucose regulation in artificial pancreas

GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

Review on pharmacokinetic/pharmacodynamic models of the related agents of incretin

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists

Glucose-insulin mathematical model for the combined effect of medications and life style of Type 2 diabetic patients

A statistical virtual patient population for the glucoregulatory system in type 1 diabetes with integrated exercise model